Edwards Lifesciences Corporation (EW) Stock Analysis
Score AGrowth · Grade A · Bullish
$82.33
$68.88
-16.3%
10/10
A
Growth
Investment Thesis
Good opportunity: Solid company with good risk/reward at 9.8:1.
For New Investors
Quantitative score: high
For Current Holders
Quantitative score: neutral
Buy if
- Price drops 15-20% (improves asymmetry)
- Bull scenario catalysts materialize
- Market-wide correction creates opportunity
Sell if
- Bear scenario triggers occur
- Quality metrics deteriorate (ROIC declining)
- Better alternatives emerge
Valuation
Fair Value estimate: $68.88 (-16.3%). Overvalued vs fundamentals.
PEG-Based EPS
$123.49
FCF DCF Model
$62.08
EV/EBITDA
$70.92
Blended Fair Value
$68.88
Confidence
Medium
Methods
PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA, Revenue Multiple
Quality Analysis
101/120 points
Investable
ROE (3Y Avg)
24.4%
ROIC-WACC Spread
2.8%
D/E Ratio
0.1x
Current Ratio
3.7x
Interest Coverage
99x
FCF Positive Years
3/3
Quality Flags
- ROIC spread: 2.8pp (got 7/25 pts)
- Leverage: D/E 0.1x (14/15 pts)
Market Sentiment
Wall Street Consensus
$95.00
+15.4% Upside
27 analysts
Range: $85.00 — $110.00
Rating: Buy
Our model aligns with Wall Street consensus.
Trend & Technical
Price ($82.43) is 1.4% above SMA 200 ($81.26). Bullish trend confirmed.
Tech Score 90/100 — MOMENTUM ALIGNMENT. Healthy uptrend confirmed by RSI and MACD. Technical tailwind.
Risk & Reward
Asymmetry Ratio
9.77:1
Expected Return
+55.1%
Bull Upside
+97.7%
Bear Downside
-10.0%
Excellent asymmetry: 9.77:1 ratio. Upside significantly outweighs downside.
Verdict: Very Favorable
Scenario Analysis
Bear
Base
Bull
Buy Zone & Action Plan
See exact entry zones, stop-loss levels, and a personalized action plan.
AI Executive Summary
Get a detailed AI-written breakdown of the investment thesis, risks, and catalysts.
Technical Analysis
RSI, MACD, moving averages, trend signals, and momentum indicators.
Ask AI about this stock
Chat with our AI analyst to ask questions about valuation, risks, or comparisons.
Frequently Asked Questions
What is the fair value of EW?
Based on our multi-method conviction analysis, the estimated fair value of Edwards Lifesciences Corporation (EW) is $68.88. This is calculated by blending PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA, Revenue Multiple and applying a quality premium of 0% based on the company's fundamentals. The confidence level of this estimate is medium.
Is EW a buy, sell, or hold?
EW currently has a BUY rating with a conviction score of 10/10. Good opportunity: Solid company with good risk/reward at 9.8:1. Quantitative score: high.
Is EW a high-quality stock?
Edwards Lifesciences Corporation has a quality grade of A (101/120 points), rated as Investable. Key metrics include ROE of 24.4%, ROIC-WACC spread of 2.8%, and D/E ratio of 0.1x.
What type of stock is EW?
EW is classified as a "growth" in our framework. High P/E: 44.6x, Low dividend (reinvesting): 0.0%, Mature growth: 6.1%, Moderate growth: 6.1%, Market-like beta: 0.87
What do Wall Street analysts say about EW?
27 Wall Street analysts have a consensus price target of $95.00 for EW, representing +15.4% upside. Targets range from $85.00 to $110.00. The consensus recommendation is "Buy". Our model aligns with Wall Street consensus.
What are the risks of investing in EW?
The risk/reward asymmetry ratio for EW is 9.77:1, rated as Very Favorable. Excellent asymmetry: 9.77:1 ratio. Upside significantly outweighs downside. The expected return is +55.1%, with bull case upside of +97.7% and bear case downside of -10.0%.
What is the current trend for EW?
EW is in a bullish trend. Price ($82.43) is 1.4% above SMA 200 ($81.26). Bullish trend confirmed. The technical score is 90/100.
Related Stock Analyses
Best Stocks to Buy
Get the complete analysis
Scenario targets, buy zones, action plan, executive summary, technical analysis, and AI chat. All free.
Last updated: May 19, 2026 · Framework version 3.7
This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.